{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:54Z","timestamp":1791912474584,"version":"4.3.4"},"reference-count":89,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Myasthenia gravis is an antibody-mediated autoimmune condition characterized by defects in cholinergic transmission at the neuromuscular junction. In AchR antibody-positive patients, complement activation plays a prominent role in the disease process, which appears to be mediated by the activation of the membrane attack complex. Since IgG4 is not a good complement activator, the role of complement in MuSK antibody-positive myasthenia gravis patients is negligible. Experimental animal models of myasthenia gravis have shown promise with the antagonism of different elements of the complement cascade, with positive clinical outcomes. This has led to the development of the first C5 inhibitors approved for myasthenia gravis with AchR antibodies: eculizumab, ravulizumab, and zilucoplan. Other clinical trials are currently in progress, investigating the potential therapeutic role of other targets, including the Factor B inhibition or hepatic synthesis of the C5 protein. Other proposed potential targets that have not yet been clinically tested are also discussed in this review article.<\/jats:p>","DOI":"10.3390\/cells14100739","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:54:28Z","timestamp":1747724068000},"page":"739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0785-5645","authenticated-orcid":false,"given":"Armando","family":"Martinez Salazar","sequence":"first","affiliation":[{"name":"Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Mokhtari","sequence":"additional","affiliation":[{"name":"Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"},{"name":"Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Peguero","sequence":"additional","affiliation":[{"name":"Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"},{"name":"Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-2346","authenticated-orcid":false,"given":"Muhammad","family":"Jaffer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"},{"name":"Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dresser, L., Wlodarski, R., Rezania, K., and Soliven, B. (2021). Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112235"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"San, P.P., and Jacob, S. (2023). Role of complement in myasthenia gravis. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1277596"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lazaridis, K., and Tzartos, S.J. (2020). Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00212"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molimm.2022.08.018","article-title":"Complement and myasthenia gravis","volume":"151","author":"Sanderson","year":"2022","journal-title":"Mol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.1127142","article-title":"The muscle protein Dok-7 is essential for neuromuscular synaptogenesis","volume":"312","author":"Okada","year":"2006","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chuquisana, O., Stascheit, F., Keller, C.W., Pu\u010di\u0107-Bakovi\u0107, M., Patenaude, A.-M., Lauc, G., Tzartos, S., Wiendl, H., Willcox, N., and Meisel, A. (2024). Functional Signature of LRP4 Antibodies in Myasthenia Gravis. Neurol. Neuroimmunol. Neuroinflamm., 11.","DOI":"10.1212\/NXI.0000000000200220"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: A multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","article-title":"Effect of complement and its regulation on myasthenia gravis pathogenesis","volume":"4","author":"Kusner","year":"2008","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-5728(96)00133-6","article-title":"Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barr\u00e9 syndrome, myasthenia gravis and dermatomyositis","volume":"71","author":"Basta","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Neal","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","article-title":"Complement in human diseases: Lessons from complement deficiencies","volume":"46","author":"Botto","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sanghvi, S.Y., and Schwartz, R.A. (2021). Leiner\u2019s disease (erythroderma desquamativum): A review and approach to therapy. Dermatol. Ther., 34.","DOI":"10.1111\/dth.14510"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12016-014-8453-8","article-title":"Vasculitides and the Complement System: A Comprehensive Review","volume":"49","author":"Chimenti","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lung, T., Sakem, B., Risch, L., W\u00fcrzner, R., Colucci, G., Cerny, A., and Nydegger, U. (2019). The complement system in liver diseases: Evidence-based approach and therapeutic options. J. Transl. Autoimmun., 2.","DOI":"10.1016\/j.jtauto.2019.100017"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0022-3476(82)80633-1","article-title":"Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome","volume":"100","author":"Ballow","year":"1982","journal-title":"J. Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1040-8428(99)00052-9","article-title":"Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria","volume":"33","author":"Boccuni","year":"2000","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IJGM.S88552","article-title":"Animal models of myasthenia gravis: Utility and limitations","volume":"9","author":"Mantegazza","year":"2016","journal-title":"Int. J. Gen. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1136\/jnnp.43.7.568","article-title":"Experimental autoimmune myasthenia gravis","volume":"43","author":"Lindstrom","year":"1980","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1034\/j.1600-065x.2001.1840111.x","article-title":"Rat models as tool to develop new immunotherapies","volume":"184","author":"Link","year":"2001","journal-title":"Immunol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.expneurol.2015.02.025","article-title":"Guidelines for pre-clinical assessment of the acetylcholine receptor\u2013specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs","volume":"270","author":"Kusner","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune response to acetylcholine receptor","volume":"180","author":"Patrick","year":"1973","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.expneurol.2015.03.010","article-title":"Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors\u2013Recommendations for methods and experimental designs","volume":"270","author":"Losen","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/332738a0","article-title":"The binding site for C1q on IgG","volume":"332","author":"Duncan","year":"1988","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.13411","article-title":"Carbamylation reduces the capacity of IgG for hexamerization and complement activation","volume":"200","author":"Lubbers","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Oskam, N., Damelang, T., Streutker, M., Ooijevaar-de Heer, P., Nouta, J., Koeleman, C., Van Coillie, J., Wuhrer, M., Vidarsson, G., and Rispens, T. (2023). Factors affecting IgG4-mediated complement activation. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1087532"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Dekkers, G., Treffers, L., Plomp, R., Bentlage, A.E.H., de Boer, M., Koeleman, C.A.M., Lissenberg-Thunnissen, S.N., Visser, R., Brouwer, M., and Mok, J.Y. (2017). Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00877"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chinello, C., de Haan, N., Capitoli, G., Trezzi, B., Radice, A., Pagani, L., Criscuolo, L., Signorini, S., Galimberti, S., and Sinico, R.A. (2022). Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094664"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nm0395-237","article-title":"Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein","volume":"1","author":"Malhotra","year":"1995","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vakrakou, A.G., Karachaliou, E., Chroni, E., Zouvelou, V., Tzanetakos, D., Salakou, S., Papadopoulou, M., Tzartos, S., Voumvourakis, K., and Kilidireas, C. (2023). Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1212757"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Preston, D., and Shapiro, B. (2021). Electromyography and Neuromuscular Disorders: Clinical-Electrodiagnostic-Ultrasound Correlations, Fourth Edition. J. Clin. Neurophysiol., 38.","DOI":"10.1097\/WNP.0000000000000842"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1749-6632.2012.06841.x","article-title":"Neuromuscular transmission failure in myasthenia gravis: Decrement of safety factor and susceptibility of extraocular muscles","volume":"1275","author":"Serra","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410430315","article-title":"End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis","volume":"43","author":"Ruff","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2008.04.038","article-title":"How myasthenia gravis alters the safety factor for neuromuscular transmission","volume":"201\u2013202","author":"Ruff","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vilquin, J.-T., Bayer, A.C., Le Panse, R., and Berrih-Aknin, S. (2019). The Muscle Is Not a Passive Target in Myasthenia Gravis. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01343"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00401-022-02493-6","article-title":"Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities","volume":"144","author":"Rose","year":"2022","journal-title":"Acta Neuropathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jnnp.43.7.577","article-title":"Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes","volume":"43","author":"Engel","year":"1980","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: Quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.expneurol.2012.06.034","article-title":"Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors","volume":"237","author":"Morsch","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Aguirre, F., Manin, A., Fernandez, V.C., Justo, M.E., Leoni, J., Paz, M.L., and Villa, A.M. (2020). C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis. Ther. Adv. Neurol. Disord., 13.","DOI":"10.1177\/1756286420935697"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/ene.15730","article-title":"Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis","volume":"30","author":"Stascheit","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_47","first-page":"851","article-title":"Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis","volume":"70","author":"Huang","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Nelke, C., Schroeter, C.B., Barman, S., Stascheit, F., Masanneck, L., Theissen, L., Huntemann, N., Walli, S., Cengiz, D., and Dobelmann, V. (2024). Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering. eBioMedicine, 105.","DOI":"10.1016\/j.ebiom.2024.105231"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-5728(00)00394-5","article-title":"Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations","volume":"111","author":"Romi","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.18632\/aging.204156","article-title":"Integrated proteomics and metabolomics analysis reveals hubs protein and network alterations in myasthenia gravis","volume":"14","author":"Tong","year":"2022","journal-title":"Aging"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Jin, L., He, D., Zeng, Q., Tan, S., Shi, J., Liu, Y., Zou, Z., Song, J., Yan, C., and Huan, X. (2024). Eculizumab in thymoma-associated myasthenia gravis: A real-world cohort study. Ther. Adv. Neurol. Disord., 17.","DOI":"10.1177\/17562864241309431"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.21037\/jtd-24-824","article-title":"The impact of immune markers on thymectomy prognosis in thymoma-myasthenia gravis","volume":"16","author":"Wang","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm-19-363","article-title":"Serological diagnosis of myasthenia gravis and its clinical significance","volume":"11","author":"Li","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Jiao, L., Li, H., and Guo, S. (2022). Eculizumab treatment for myasthenia gravis subgroups: 2021 update. J. Neuroimmunol., 362.","DOI":"10.1016\/j.jneuroim.2021.577767"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A Review in Generalized Myasthenia Gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/mus.27656","article-title":"Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_60","unstructured":"Lathia, C., Gao, X., Kassir, N., Mouksassi, S., Jayaraman, B., Marier, J.F., Wang, J., and Bedrosian, C.L. (2015). Population pharmacokinetic and pharmacodynamic analysis of eculizumab to support phase 3 dosing regimen in patients with refractory generalized myasthenia gravis. Clinical Pharmacology & Therapeutics, Wiley-Blackwell."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Monteleone, J.P.R., Gao, X., Kleijn, H.J., Bellanti, F., and Pelto, R. (2021). Eculizumab Pharmacokinetics and Pharmacodynamics in Patients with Generalized Myasthenia Gravis. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.696385"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Murai, H., Uzawa, A., Suzuki, Y., Imai, T., Shiraishi, H., Suzuki, H., Okumura, M., O\u2019Brien, F., Wang, J.J., and Fujita, K.P. (2019). Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. J. Neurol. Sci., 407.","DOI":"10.1016\/j.jns.2019.08.004"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14712598.2020.1725468","article-title":"Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"20","author":"Lee","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sheridan, D., Yu, Z.X., Zhang, Y., Patel, R., Sun, F., Lasaro, M.A., Bouchard, K., Andrien, B., Marozsan, A., and Wang, Y. (2018). Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195909"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2147\/NDT.S374694","article-title":"Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence","volume":"19","author":"Vu","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu","year":"2023","journal-title":"J. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Vu, T., Meisel, A., Mantegazza, R., Annane, D., Katsuno, M., Aguzzi, R., Enayetallah, A., Beasley, K.N., Rampal, N., and Howard, J.F. (2022). Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid., 1.","DOI":"10.1056\/EVIDoa2100066"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J. Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mus.28044","article-title":"Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study","volume":"69","author":"Howard","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/mus.28037","article-title":"Novel uses of complement inhibitors in myasthenia gravis-Two case reports","volume":"69","author":"Zadeh","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis","volume":"30","author":"Howard","year":"2021","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Howard, J.F., Bresch, S., Farmakidis, C., Freimer, M., Genge, A., Hewamadduma, C., Hinton, J., Hussain, Y., Juntas-Morales, R., and Kaminski, H.J. (2024). Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: Interim analysis of the RAISE-XT open-label extension study. Ther. Adv. Neurol. Disord., 17.","DOI":"10.1177\/17562864241243186"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s00415-024-12209-3","article-title":"Improvement of fatigue in generalised myasthenia gravis with zilucoplan","volume":"271","author":"Weiss","year":"2024","journal-title":"J. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","article-title":"The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis","volume":"38","author":"Ma","year":"2024","journal-title":"CNS Drugs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1007\/s12325-024-03014-5","article-title":"Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis","volume":"41","author":"Smith","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Pane","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Devalaraja-Narashimha, K., Huang, C., Cao, M., Chen, Y.P., Borodovsky, A., Olson, W.C., Morton, L.G., and Retter, M.W. (2022). Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0269749"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.molimm.2023.12.004","article-title":"Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration","volume":"165","author":"Jindal","year":"2024","journal-title":"Mol. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/bloodadvances.2020001690","article-title":"Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes","volume":"4","author":"Lin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Lekova, E., Zelek, W.M., Gower, D., Spitzfaden, C., Osuch, I.H., John-Morris, E., Stach, L., Gormley, D., Sanderson, A., and Bridges, A. (2022). Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.968206"},{"key":"ref_84","first-page":"430","article-title":"Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals","volume":"83","author":"Orren","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: Mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000463204","article-title":"Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies","volume":"8","author":"Schulze","year":"1991","journal-title":"Complement. Inflamm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel Immunotherapies for Myasthenia Gravis","volume":"12","author":"Nair","year":"2023","journal-title":"Immunotargets Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic Variants in C5 and Poor Response to Eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2024026299","article-title":"Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH","volume":"145","author":"Kulasekararaj","year":"2025","journal-title":"Blood"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/10\/739\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:53Z","timestamp":1760031293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/10\/739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":89,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cells14100739"],"URL":"https:\/\/doi.org\/10.3390\/cells14100739","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}